

# CITATION REPORT

List of articles citing

## Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases

DOI: 10.1177/0961203396005001041

Lupus, 1996, 5, 11-15.

**Source:** <https://exaly.com/paper-pdf/27010268/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
111	The use of antimalarials in dermatology. <b>2000</b> , 11, 185-194		2
110	Dosing of antirheumatic drugs in renal disease and dialysis. <b>2004</b> , 10, 190-204		10
109	Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. <b>2005</b> , 94, 1389-95		40
108	Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. <b>2008</b> , 112, 1687-95		166
107	Perioperative management of immunosuppression in rheumatic diseases--what to do?. <b>2010</b> , 30, 999-1004		23
106	Treatment of cutaneous lupus erythematosus. <i>Lupus</i> , <b>2010</b> , 19, 1125-36	2.6	33
105	The role of antimalarial agents in the treatment of SLE and lupus nephritis. <b>2011</b> , 7, 718-29		166
104	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. <b>2012</b> , 8, 522-33		145
103	Hydroxychloroquine retinopathy after short-term therapy. <b>2014</b> , 8, 67-9		8
102	Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli. <b>2015</b> , 59, 7680-6		19
101	Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2017</b> , 958-982.e7		2
100	Development of a novel ion-pairing HPLC-FL method for the separation and quantification of hydroxychloroquine and its metabolites in whole blood. <b>2018</b> , 32, e4258		9
99	Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver. <b>2018</b> , 107, 1478-1488		25
98	Implant delivering hydroxychloroquine attenuates vaginal T lymphocyte activation and inflammation. <b>2018</b> , 277, 102-113		10
97	A tumor-activatable particle with antimetastatic potential in breast cancer via inhibiting the autophagy-dependent disassembly of focal adhesion. <b>2018</b> , 168, 1-9		17
96	Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine. <b>2018</b> , 31, e12660		8
95	Antimalarials - are they effective and safe in rheumatic diseases?. <b>2018</b> , 56, 164-173		51

94	Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis. <b>2019</b> , 98, e15030	14
93	Chloroquine Is Effective for Maintenance of Remission in Autoimmune Hepatitis: Controlled, Double-Blind, Randomized Trial. <b>2019</b> , 3, 116-128	11
92	Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. <b>2020</b> , 31, 2475-2489	6
91	A case report of toxic epidermal necrolysis (TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime?. <b>2020</b> , 18, 19	12
90	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. <b>2020</b> , 108, 1135-1149	17
89	Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations. <b>2020</b> , 886, 173454	7
88	Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. <b>2020</b> , 38, 2209-2217	21
87	Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. <b>2020</b> , 25, 497-502	2
86	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <b>2020</b> , 2, 491-495	3
85	Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. <b>2020</b> , 43, 765-772	36
84	Antimalarials as Antivirals for COVID-19: Believe it or Not!. <b>2020</b> , 360, 618-630	14
83	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. <b>2020</b> , 13, 531-542	5
82	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <b>2020</b> , 17, e1003252	55
81	Drug repurposing approach to fight COVID-19. <b>2020</b> , 72, 1479-1508	165
80	COVID-19 as an Acute Inflammatory Disease. <b>2020</b> , 205, 12-19	74
79	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. <b>2020</b> , 9, 215-221	79
78	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. <b>2020</b> , 35, 101735	71
77	Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update. <b>2020</b> , 35, 274-284	18

76	Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. <b>2020</b> , 174, e202422	22
75	In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <b>2020</b> , 71, 732-739	1644
74	Efficient degradation of chloroquine drug by electro-Fenton oxidation: Effects of operating conditions and degradation mechanism. <b>2020</b> , 260, 127558	37
73	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. <b>2020</b> , 16, 155-166	596
72	Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. <b>2020</b> , 40, 387-388	21
71	Antimalarial Agents. <b>2021</b> , 234-244.e4	1
70	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. <b>2021</b> , 19, 5-16	15
69	AZD9291 Resistance Reversal Activity of a pH-Sensitive Nanocarrier Dual-Loaded with Chloroquine and FGFR1 Inhibitor in NSCLC. <b>2021</b> , 8, 2002922	10
68	Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. <b>2021</b> , 51, 127-138	4
67	UHPLC-MS/MS Method for Determination of Hydroxychloroquine and Its Main Metabolites in Oral Fluid and Whole Blood for Therapeutic Drug Monitoring. <b>2021</b> , 6, 868-880	0
66	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. <b>2021</b> , 13, 1759720X211002595	2
65	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. <b>2021</b> , 23, 5	8
64	A comprehensive review on the biological interest of quinoline and its derivatives. <b>2021</b> , 32, 115973	70
63	Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19. <b>2021</b> , 25, 1905-1927	8
62	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. <b>2021</b> ,	1
61	Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. <b>2021</b> , 12, 625678	7
60	4-Aminoquinoline compounds from the Spanish flu to COVID-19. <b>2021</b> , 135, 111138	3
59	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. <b>2021</b> , 13, 259-284	12

58 COVID-19: Antiviral Tedavi.

57 Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. **2021**, 41, 1189-1202 5

56 Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective. **2021**, 12, 596855 8

55 Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. **2021**, 151, 112106 3

54 The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. **2021**, 10, 100085 5

53 Hydroxychloroquine: Pharmacological, physicochemical aspects and activity enhancement through experimental formulations. **2021**, 63, 102512 0

52 Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. **2021**, 139, 111642 19

51 A review on the pharmacokinetic properties and toxicity considerations for chloroquine and hydroxychloroquine to potentially treat coronavirus patients. **2021**, 1-12 2

50 Dependence of Viscosity and Diffusion on  $\beta$ -Cyclodextrin and Chloroquine Diphosphate Interactions. **2021**, 9, 1433 1

49 COVID-19: potential therapeutics for pediatric patients. **2021**, 73, 1520-1538 6

48 Scoping insight on antiviral drugs against COVID-19.. **2021**, 14, 103385 0

47 Antimalarial drugs (and lupus). **2021**, 601-609

46 Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. **2021**, 28, 40431-40444 13

45 Traditional DMARDs: Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. **2013**, 917-940.e6 2

44 Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin. **2020**, 316, 280-284 44

43 Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. **2020**, 101, 283-289 24

42 Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. *Saudi Pharmaceutical Journal*, **2020**, 28, 1333-1352 4-4 11

41 Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations. **2020**, 129, 104842 13

40	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. <b>2020</b> , 42, 360-368	25
39	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <b>2020</b> , 9,	9
38	Computational screening for potential drug candidates against the SARS-CoV-2 main protease. <b>2020</b> , 9, 514	7
37	Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020. <b>2020</b> , 69, 1210-1215 <sup>38</sup>	38
36	Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters. <b>2020</b> , 21, 1127-1135	7
35	Chloroquine and Hydroxychloroquine Toxicity. 2, 8	3
34	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <b>2020</b> , 11, 597985	13
33	Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine. <b>2020</b> , 26,	6
32	Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms. <b>2021</b> , 912, 174548	3
31	Pharmacokinetics and Toxicokinetics of Artemisinin-Hydroxychloroquine Sulfate Tablets in Rats and Dogs. <b>2021</b> , 2021, 6830459	1
30	SYSTEMIC LUPUS ERYTHEMATOSUS. <b>2009</b> , 1047-1062	
29	Methotrexate, Leflunomide, Sulfasalazine, Hydroxychloroquine, and Combination Therapies. <b>2009</b> , 883-907	0
28	Disease-Modifying Antirheumatic Drug Use in Older Rheumatoid Arthritis Patients. <b>2011</b> , 151-172	
27	Nonimmunosuppressive disease-modifying antirheumatic drugs. <b>2015</b> , 434-442	1
26	Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu. <b>2020</b> ,	
25	Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19. <b>2020</b> , 21, 427-435	1
24	Role of lipid Nanoparticles in COVID-19 inrepurposing drugs and vaccines. <b>2021</b> , 17,	
23	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <b>2021</b> , 9,	9

22	Grammatical evolution-based design of SARS-CoV-2 main protease inhibitors.. <b>2022,</b>		0
21	Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions.. <b>2022,</b> 15, 23		0
20	Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial.. <b>2022,</b> 17, e0261980		3
19	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. <b>2022,</b> 14, 1759720X2114073001		0
18	Quantitative analysis of favipiravir and hydroxychloroquine as FDA-approved drugs for treatment of COVID-19 using synchronous spectrofluorimetry. Application to pharmaceutical formulations and biological fluids.. <b>2022,</b>		1
17	Mechanism of Action and Efficacy of Immunosuppressors in Lupus Nephritis.. <b>2021,</b> 14, 441-458		2
16	Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients.. <b>2021,</b> 23,		0
15	Hydroxychloroquine Causes Early Inner Retinal Toxicity and Affects Autophagosome-Lysosomal Pathway and Sphingolipid Metabolism in the Retina.. <b>2022,</b> 1		0
14	Physiologically-Based Pharmacokinetics Modeling for Hydroxychloroquine as a Treatment for Malaria and Optimized Dosing Regimens for Different Populations. <b>2022,</b> 12, 796		0
13	Antimalarial agents. <b>2013,</b> 241-251.e3		3
12	COVID-19 in G6PD-deficient patients, oxidative stress, and neuropathology.. <b>2022,</b>		1
11	The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia. <i>Saudi Pharmaceutical Journal,</i> <b>2022,</b>	4.4	0
10	Recent Advancements in Electrochemical Sensors for 4-Aminoquinoline Drugs Determination in Biological and Environmental Samples. <i>Journal of the Electrochemical Society,</i>	3.9	1
9	Intérêt des dosages pharmacologiques d'immunosuppresseurs et immunomodulateurs dans la prise en charge des maladies autoimmunes. <i>Revue De Medecine Interne,</i> <b>2022,</b>	0.1	1
8	Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). <i>Journal of Heterocyclic Chemistry,</i>	1.9	0
7	Interaction of chloroquine with 2-(hydroxypropyl)- $\beta$ -cyclodextrin through the supramolecular assembly for cytotoxicity on breast cancer cell lines.		0
6	Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic.		0
5	Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.		0

- 4 A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer. **2022**, 2, 431-443
- 3 Bewertung von Wechselwirkungen und Dosierungsempfehlungen von synthetischen DMARDs   
Evidenz- und konsensbasierte Empfehlungen auf Basis einer systematischen Literatursuche.
- 2 Ultrasonic-Assisted Fabrication of MIL-100(Fe) Metal-Organic Frameworks as a Carrier for the Controlled Delivery of the Chloroquine Drug. **2023**, 8, 1262-1270
- 1 Predicting Hydroxychloroquine Clearance in healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach. **2023**, 15, 1250